Abcam, ab96587, Anti-ZO1 tight junction protein antibody

Size: 50µL
Anti-ZO1 tight junction protein antibody (ab96587) is a rabbit polyclonal antibody detecting ZO1 tight junction protein in Western Blot, ICC/IF . Suitable for Human, Mouse . - Over 180 publications - Trusted since 2010
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human, Rat,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human TJP1 aa 1-300. The exact immunogen used to generate this antibody is proprietary information.Q07157

Product details:
Product Specifications
Anti-ZO1 tight junction protein antibody (ab96587) is a rabbit polyclonal antibody and is validated for use in ICC/IF, WB in human, mouse samples.
Anti-ZO1 tight junction protein antibody (ab96587) specifically detects ZO1 tight junction protein (UniProt ID: Q07157; Molecular weight: 195kDa) and is sold in 50 µL selling sizes.
Quality and Validation
Abcam's high quality validation processes ensure Anti-ZO1 tight junction protein antibody (ab96587) has high sensitivity and specificity.
Anti-ZO1 tight junction protein antibody (ab96587) has been cited over 185 times in peer reviewed journals and is trusted by the scientific community.
Anti-ZO1 tight junction protein antibody (ab96587) has 4 independent reviews from customers.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7Preservative: 0.025% Proclin 300Constituents: PBS, 20% Glycerol (glycerin, glycerine), Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ZO1 tight junction protein also known as TJP1 is a critical component of tight junctions in epithelial and endothelial cells. It is a 225 kDa protein that plays a mechanical role in stabilizing cell-cell junctions by linking the actin cytoskeleton to tight junction membrane proteins. ZO1 is expressed in various tissues including the liver kidney and brain where it is essential for maintaining cell polarity and permeability barriers. It acts as a scaffold facilitating the organization of other tight junction proteins.
Biological function summary
ZO1 tight junction protein maintains cellular barriers and regulates paracellular permeability. This protein forms part of the tight junction complex with other proteins like occludin and claudins contributing to cellular integrity. ZO1's presence at tight junctions helps control the passage of ions and molecules between cells therefore ensuring selective permeability while protecting tissue function. Its ability to interact with multiple proteins enables it to coordinate complex signaling mechanisms that are important for cell adhesion and communication.
Pathways
The tight junction protein ZO1 participates in important signaling pathways like the epithelial barrier formation pathway and the actin cytoskeleton regulation pathway. It interacts with proteins like ZO2 and ZO3 which are critical for enhancing barrier function and cytoskeletal dynamics. By participating in these pathways ZO1 helps mediate both the structural and signaling functions necessary for maintaining tissue homeostasis and responding to cellular stress or injury.
ZO1 protein plays a role in conditions such as inflammatory bowel disease (IBD) and cancer. In IBD the disruption of ZO1 leads to compromised intestinal barriers contributing to disease pathogenesis. The loss or mislocalization of ZO1 has been associated with tumorigenesis in cancers where its interaction with other junctional proteins like claudins could influence cancer cell invasiveness. Understanding ZO1's involvement in these disorders provides insights into potential therapeutic targets for improving epithelial barrier function.